ResMed Inc.
RMDHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, ResMed Inc. (RMD) is listed under Medical Instruments & Supplies. Valued at $35.56B, RMD is a large-cap name in its sector. It operates in two segments, Sleep and Breathing Health, and Residential Care Software.
Market Cap
$35.56B
Beta
0.75
P/E (TTM)
24.24
P/E (Fwd)
19.08
EPS (TTM)
$10.43
EPS (Fwd)
$13.26
ROE
24.3%
ROA
14.0%
Cash
$1.47B
Total Debt
$825.9M
Free CF
$939.2M
52W Change
-2.5%
Annual Financials
Cash vs Debt
Where RMD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RMD finished 11.70% above its 150-day moving average ($214.65) and 6.98% above its 200-day moving average ($224.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RMD overbought or oversold?
At the October 20, 2026 close, RMD's RSI(14) was 73.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ResMed Inc. holds $1.47B in cash against $825.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $939.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 24.3%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 14.0% further supports the picture of efficient asset utilization. Revenue has grown from $4.22B (2023) to $5.65B (2026), reflecting a 34% increase over the period.
As with any equity investment, RMD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ResMed Inc. and its sector.